Merck KGaA's earnings beat consensus on lab equipment, drug sales
Reuters
Published Nov 10, 2022 01:06AM ET
Updated Nov 10, 2022 05:47AM ET
By Ludwig Burger
FRANKFURT (Reuters) -Germany's Merck KGaA reported better-than-expected quarterly earnings on higher revenues from drugs and biotech lab equipment, but signalled that growth of its semiconductor chemicals unit could lose momentum next year.
Third-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, rose 16.7% to 1.81 billion euros, surpassing the average estimate of 1.78 billion euros in an analyst poll on the company's website.
The diversified group narrowed on Thursday its full-year target range for adjusted EBITDA to between 6.80 billion and 7.20 billion euros, against a previous forecast of 6.75 billion to 7.25 billion.
Merck said the outlook for its life science unit, which makes substances and gear for drugmakers, had brightened further after cost cuts and as drugmakers upgrade their lab equipment to pursue new technologies.
But the shares declined as the company said its electronics unit was now expected to see earnings fall as much as a currency-adjusted 10%, on a drop in demand for its liquid crystals used in display screens.
The stock was down 2.4% by 1010 GMT, paring some of its strong gains over the prior two trading sessions.
Within the electronics unit, demand for chemicals used by the semiconductor industry was still growing, but likely not next year, Chief Executive Belen Garijo said on a media call.
"A cool-down in semi chips could happen in 2023," she said.
Last month Garijo told Reuters that she did not anticipate that a projected decline in smartphone sales this year would weigh on the semiconductor chemicals business any time soon.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.